Scinai Immunotherapeutics Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The firm's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
How did SCNI's recent EPS compare to expectations?
The most recent EPS for Scinai Immunotherapeutics Ltd is $-4.7, not beating expectations of $-6.32.
How did Scinai Immunotherapeutics Ltd SCNI's revenue perform in the last quarter?
Scinai Immunotherapeutics Ltd revenue for the last quarter is $-4.7
What is the revenue estimate for Scinai Immunotherapeutics Ltd?
According to of Wall street analyst, the revenue estimate of Scinai Immunotherapeutics Ltd range from $ to $
What's the earning quality score for Scinai Immunotherapeutics Ltd?
Scinai Immunotherapeutics Ltd has a earning quality score of B/43.63153. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Scinai Immunotherapeutics Ltd report earnings?
Scinai Immunotherapeutics Ltd next earnings report is expected in 2024-08-13
What are Scinai Immunotherapeutics Ltd's expected earnings?
Scinai Immunotherapeutics Ltd expected earnings is $0.0, according to wall-street analysts.
Did Scinai Immunotherapeutics Ltd beat earnings expectations?
Scinai Immunotherapeutics Ltd recent earnings of $0.0 does not beat expectations.